Structure via PubChem · Public domain (PubChem)
conivaptan
Sign in to saveAlso known as Vaprisol®, YM-087, YM087, 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide, 4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). Additionally, conivaptan is used for the treatment of syndrome of inappropriate antidiuretic hormone secretion.
Chemical data
- Formula
- C32H26N4O2
- Molecular weight
- 498.6 g/mol
- IUPAC name
- N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
- SMILES
- CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
- InChIKey
- IKENVDNFQMCRTR-UHFFFAOYSA-N
- XLogP
- 5.7
- Polar surface area
- 78.1 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2005
- Admin. routes
- parenteral
- Indications
- cardiovascular disease, cirrhosis of liver, heart failure, Hyponatremia
via ChEMBL · EBI
Research
281 papers- Conivaptan: YM 087.Drugs in R&D · 2004
- Conivaptan: new treatment for hyponatremia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2007
- Conivaptan (Yamanouchi).Current opinion in investigational drugs (London, England : 2000) · 2002
- Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.The Annals of pharmacotherapy · 2013
- Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].Cardiovascular drug reviews · 2007
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 498.205576
- Has use
- medication
Show 4 more facts
- chemical formula
- C₃₂H₂₆N₄O₂
- canonical SMILES
- CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
- World Health Organisation international non-proprietary name
- conivaptan
- Commons category
- Conivaptan
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Pharmacology
- Adverse effects
- Chemistry
- History
- References
- External links
Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). Additionally, conivaptan is used for the treatment of syndrome of inappropriate antidiuretic hormone secretion.
Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1A and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.
Excerpted from Wikipedia’s “conivaptan” article, available under the CC BY-SA 4.0 licence.
Available in 11 languages
via Wikidata sitelinks · CC0